.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 8,846,625

« Back to Dashboard

Details for Patent: 8,846,625

Title:Glucagon-like peptide-2 analogs
Abstract: Analogs of glucagon-like peptide 2, a product of glucagon gene expression, have been identified as intestinal tissue growth factors. Their formulation as pharmaceutical, and therapeutic use in treating disorders of the small bowel, are described.
Inventor(s): Drucker; Daniel J (Toronto, CA), Crivici; Anna E. (Laguna Niguel, CA), Sumner-Smith; Martin (Palgrave, CA)
Assignee: 1149336 Ontario Inc. (CA)
Filing Date:Mar 11, 2013
Application Number:13/794,314
Claims:1. An intestinotrophic GLP-2 analog of SEQ ID NO: 2, wherein at least one amino acid at one or more positions selected from the group consisting of positions 1, 5, 7, 16-18, 25, and 33 is substituted with an amino acid other than a wild type, mammalian GLP-2 residue; wherein positions 2-4, 6, 8-15, 19-24, and 26-32 are unmodified, and wherein 4 to 8 residues are optionally deleted from the C-terminus of SEQ ID NO: 2.

2. The GLP-2 analog according to claim 1, wherein said analog incorporates at least one amino acid substitution selected from the group consisting of: a) incorporation of Pro, Asp, or desNH.sub.2Tyr at position 1; b) incorporation of Thr or Ala at position 5; c) incorporation of Ala at position 7; d) incorporation of Ser at position 16; e) incorporation of Arg at position 17; f) incorporation of Arg at position 18; g) incorporation of Phe or Tyr at position 25; and h) incorporation of Glu at position 33.

3. The GLP-2 analog according to claim 1 selected from the group consisting of: [Pro.sup.1]hGLP-2(1-33); [Asp.sup.1]hGLP-2 (1-33); [desNH.sub.2Tyr.sup.1]hGLP-2 (1-33); [Thr.sup.5]hGLP-2 (1-33); [Ser.sup.16, Arg.sup.17, Arg.sup.18]hGLP-2 (1-33); [Ala.sup.5, Ala.sup.7]hGLP-2 (1-33); [Glu.sup.33]hGLP-2 (1-33); [Phe.sup.25]hGLP-2 (1-33); [Tyr.sup.25]hGLP-2 (1-33).

4. A pharmaceutical composition comprising a therapeutically effective amount of a GLP-2 analog according to claim 1 and a pharmaceutically acceptable carrier.

5. A method for promoting growth of small bowel tissue in patient in need thereof, comprising the step of delivering to the patient the pharmaceutical composition of claim 4.

6. A method for treating a gastrointestinal disease, wherein the method comprises administering to a patient having the gastrointestinal disease a therapeutically effective amount of a GLP-2 analog according to claim 1, together with a pharmaceutically acceptable carrier to reduce a pathological effect or symptom of the gastrointestinal disease.

7. The method of claim 6, wherein the gastrointestinal disease is selected from the group consisting of ulcers, digestion disorders, malabsorption syndromes, short-gut syndrome, cul-de-sac syndrome, inflammatory bowel disease, celiac sprue, tropical sprue, hypogammaglobulinemic sprue, enteritis, regional enteritis (Crohn's disease), small intestinal damage due to toxic or other chemotherapeutic agents, and short bowel syndrome.

8. A method for promoting growth of small bowel tissue in a patient in need thereof, comprising the step of delivering to the patient a pharmaceutical composition comprising a therapeutically effective amount of a GLP-2 analog according to claim 3.

9. A method for treating a gastrointestinal disease, wherein the method comprises administering to a patient having the gastrointestinal disease a therapeutically effective amount of a GLP-2 analog according to claim 3 together with a pharmaceutically acceptable carrier to reduce a pathological effect or symptom of the gastrointestinal disease.

10. The method of claim 9, wherein the gastrointestinal disease is selected from the group consisting of ulcers, digestion disorders, malabsorption syndromes, short-gut syndrome, cul-de-sac syndrome, inflammatory bowel disease, celiac sprue, tropical sprue, hypogammaglobulinemic sprue, enteritis, regional enteritis (Crohn's disease), small intestinal damage due to toxic or other chemotherapeutic agents, and short bowel syndrome.

11. A method of identifying intestinotrophic analogs of GLP-2, comprising the steps of: a. obtaining a GLP-2 analog according to claim 1; b. treating a mammal with said analog using a regimen capable of eliciting an intestinotrophic effect when utilized for rat GLP-2; and c. determining the effect of said analog on small bowel weight relative to a mock treated control mammal, whereby said intestinotrophic analog of GLP-2 is identified as an analog which elicits an increase in said weight.

12. A method for promoting growth of small bowel tissue in a patient in need thereof, comprising the step of delivering to the patient a pharmaceutical composition comprising the GLP-2 analog of claim 1.

13. The peptide [desNH.sub.2Tyr.sup.1]hGLP-2(1-33).
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc